147 related articles for article (PubMed ID: 32323895)
41. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
Mao Y; Huang X; Shuang Z; Lin G; Wang J; Duan F; Chen J; Li S
Cancer Med; 2018 Apr; 7(4):1285-1296. PubMed ID: 29479816
[TBL] [Abstract][Full Text] [Related]
42. 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer.
Schlicker A; Peschke P; Bürkle A; Hahn EW; Kim JH
Int J Radiat Biol; 1999 Jan; 75(1):91-100. PubMed ID: 9972795
[TBL] [Abstract][Full Text] [Related]
43. Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.
Lombardi AJ; Hoskins EE; Foglesong GD; Wikenheiser-Brokamp KA; Wiesmüller L; Hanenberg H; Andreassen PR; Jacobs AJ; Olson SB; Keeble WW; Hays LE; Wells SI
Clin Cancer Res; 2015 Apr; 21(8):1962-72. PubMed ID: 25609062
[TBL] [Abstract][Full Text] [Related]
44. PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response.
Wurster S; Hennes F; Parplys AC; Seelbach JI; Mansour WY; Zielinski A; Petersen C; Clauditz TS; Münscher A; Friedl AA; Borgmann K
Oncotarget; 2016 Mar; 7(9):9732-41. PubMed ID: 26799421
[TBL] [Abstract][Full Text] [Related]
45. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
Vitiello PP; Martini G; Mele L; Giunta EF; De Falco V; Ciardiello D; Belli V; Cardone C; Matrone N; Poliero L; Tirino V; Napolitano S; Della Corte C; Selvaggi F; Papaccio G; Troiani T; Morgillo F; Desiderio V; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2021 Jan; 40(1):15. PubMed ID: 33407715
[TBL] [Abstract][Full Text] [Related]
46. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity.
Rieckmann T; Tribius S; Grob TJ; Meyer F; Busch CJ; Petersen C; Dikomey E; Kriegs M
Radiother Oncol; 2013 May; 107(2):242-6. PubMed ID: 23602369
[TBL] [Abstract][Full Text] [Related]
47. Patterns of protein expression in human head and neck cancer cell lines differ after proton vs photon radiotherapy.
Wang L; Yang L; Han S; Zhu J; Li Y; Wang Z; Fan YH; Lin E; Zhang R; Sahoo N; Li Y; Zhang X; Wang X; Li T; Zhu XR; Zhu H; Heymach JV; Myers JN; Frank SJ
Head Neck; 2020 Feb; 42(2):289-301. PubMed ID: 31710172
[TBL] [Abstract][Full Text] [Related]
48. Exponential Increase in Relative Biological Effectiveness Along Distal Edge of a Proton Bragg Peak as Measured by Deoxyribonucleic Acid Double-Strand Breaks.
Cuaron JJ; Chang C; Lovelock M; Higginson DS; Mah D; Cahlon O; Powell S
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):62-69. PubMed ID: 27084629
[TBL] [Abstract][Full Text] [Related]
49. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
[TBL] [Abstract][Full Text] [Related]
50. Difference in the relative biological effectiveness and DNA damage repair processes in response to proton beam therapy according to the positions of the spread out Bragg peak.
Hojo H; Dohmae T; Hotta K; Kohno R; Motegi A; Yagishita A; Makinoshima H; Tsuchihara K; Akimoto T
Radiat Oncol; 2017 Jul; 12(1):111. PubMed ID: 28673358
[TBL] [Abstract][Full Text] [Related]
51. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
52. Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis.
Noël G; Godon C; Fernet M; Giocanti N; Mégnin-Chanet F; Favaudon V
Mol Cancer Ther; 2006 Mar; 5(3):564-74. PubMed ID: 16546970
[TBL] [Abstract][Full Text] [Related]
53. Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series.
Gabrail N; Smith C
Am J Case Rep; 2020 Nov; 21():e927008. PubMed ID: 33191394
[TBL] [Abstract][Full Text] [Related]
54. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J
Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879
[TBL] [Abstract][Full Text] [Related]
55. Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation.
Liu Q; Ghosh P; Magpayo N; Testa M; Tang S; Gheorghiu L; Biggs P; Paganetti H; Efstathiou JA; Lu HM; Held KD; Willers H
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1081-9. PubMed ID: 25832698
[TBL] [Abstract][Full Text] [Related]
56. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
Verhagen CV; de Haan R; Hageman F; Oostendorp TP; Carli AL; O'Connor MJ; Jonkers J; Verheij M; van den Brekel MW; Vens C
Radiother Oncol; 2015 Sep; 116(3):358-65. PubMed ID: 25981132
[TBL] [Abstract][Full Text] [Related]
57. Targeting DNA Double-Strand Break Repair Enhances Radiosensitivity of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma to Photons and Protons.
Vitti ET; Kacperek A; Parsons JL
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32517381
[TBL] [Abstract][Full Text] [Related]
58. Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells.
Hirai T; Saito S; Fujimori H; Matsushita K; Nishio T; Okayasu R; Masutani M
Biochem Biophys Res Commun; 2016 Sep; 478(1):234-240. PubMed ID: 27425251
[TBL] [Abstract][Full Text] [Related]
59. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ;
N Engl J Med; 2019 Dec; 381(25):2391-2402. PubMed ID: 31562799
[TBL] [Abstract][Full Text] [Related]
60. Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Póti Á; Berta K; Xiao Y; Pipek O; Klus GT; Ried T; Csabai I; Wilcoxen K; Mikule K; Szallasi Z; Szüts D
Br J Cancer; 2018 Nov; 119(11):1392-1400. PubMed ID: 30425352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
